Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)

被引:41
作者
Tosetto, A. [8 ]
Balduini, C. L. [1 ]
Cattaneo, M. [2 ]
De Candia, E. [3 ]
Mariani, G. [4 ]
Molinari, A. C. [5 ]
Rossi, E. [6 ]
Siragusa, S. [7 ]
机构
[1] Univ Pavia, Fdn IRCCS Policlin San Matteo, Clin Med 3, Pavia, Italy
[2] Univ Milan, Polo San Paolo, Dipartimento Med Chirurg & Odontoiatria, UOC Med 3, Milan, Italy
[3] Univ Cattolica, Dipartimento Med Interna & Geriatr, Rome, Italy
[4] Univ Aquila, Dipartimento Ematol, Laquila, Italy
[5] IRCCS Ist Gaslini, Ctr Emofilia & Trombosi, Genoa, Italy
[6] Osped L Sacco, Serv Immunoematol & Med Trasfus, Milan, Italy
[7] Univ Palermo, UO Ematol, Dipartimento Med Interna Malattie Cardiovasc & Ne, Palermo, Italy
[8] S Bortolo Hosp, Hematol Dept, Hemophia & Thrombosis Ctr, Via Rodolfi 37, I-36100 Vicenza, Italy
关键词
RECOMBINANT FACTOR VIIA; PATIENTS RECEIVING ASPIRIN; HERMANSKY-PUDLAK-SYNDROME; BYPASS GRAFT-SURGERY; ACTIVATED FACTOR-VII; ACUTE-RENAL-FAILURE; GLANZMANNS-THROMBASTHENIA; BLOOD-TRANSFUSION; TRANEXAMIC ACID; 1-DEAMINO-8-D-ARGININE VASOPRESSIN;
D O I
10.1016/j.thromres.2009.06.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The optimal management of bleeding or its prophylaxis in patients with disorders of platelet count or function is controversial. The bleeding diathesis of these patients is usually mild to moderate: therefore, transfusion of platelet concentrates may be inappropriate, as potential adverse effects might outweigh its benefit. The availability of several anti-hemorrhagic drugs further compounds this problem, mainly because the efficacy/suitability of the various treatment options in different clinical manifestations is not well defined. In these guidelines, promoted by the Italian Society for Studies on Haemostasis and Thrombosis (Societa Italiana per lo Studio dell'Emostasi e della Trombosi [SISET]), we aim at offering the best available evidence to help the physicians involved in the management of patients with disorders of platelet count or function. Literature review and appraisal of available evidence are discussed for different clinical settings and for different available treatments, including platelet concentrates (PC), recombinant activated factor VII, desmopressin, antifibrinolytics, aprotinin and local hemostatic agents. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:E13 / E18
页数:6
相关论文
共 81 条
[1]   The use of recombinant factor VIIa in children with inherited platelet function disorders [J].
Almeida, AM ;
Khair, K ;
Hann, I ;
Liesner, R .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (03) :477-481
[2]   Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: A prospective, randomized, double-blind, placebo-controlled trial [J].
Alvarez, JM ;
Jackson, LR ;
Chatwin, C ;
Smolich, JJ .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 122 (03) :457-463
[3]  
Balduini CL, 2003, HAEMATOLOGICA, V88, P582
[4]   Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting [J].
Bidstrup, BP ;
Hunt, BJ ;
Sheikh, S ;
Parratt, RN ;
Bidstrup, JM ;
Sapsford, RN .
ANNALS OF THORACIC SURGERY, 2000, 69 (02) :541-547
[5]   Dental considerations for a Glanzmann's thrombasthenia patient - Case report [J].
Bisch, FC ;
Bowen, KJ ;
Hanson, BS ;
Kudryk, VL ;
Billman, MA .
JOURNAL OF PERIODONTOLOGY, 1996, 67 (05) :536-540
[6]   The impact of aprotinin on blood loss and blood transfusion in off-pump coronary artery bypass grafting [J].
Bittner, Hartmuth B. ;
Lemke, Janine ;
Lange, Michelle ;
Rastan, Ardawan ;
Mohr, Friedrich W. .
ANNALS OF THORACIC SURGERY, 2008, 85 (05) :1662-1668
[7]   CABG-procedures in patients with pretreatment with the GPIIb/IIIa-receptor antagonist tirofiban (Aggrastat ©):: Modification of perioperative management? [J].
Boeken, U. ;
Litmathe, J. ;
Kurt, M. ;
Feindt, P. ;
Gams, E. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 127 (02) :257-259
[8]   Successful use of recombinant factor VIIa in a patient with intractable bleeding during extracorporeal membrane oxygenation [J].
Brose, S ;
Sirbu, H ;
Engel, M ;
Kuhlen, R ;
Autschbach, R .
THORACIC AND CARDIOVASCULAR SURGEON, 2005, 53 (06) :389-390
[9]   CONTROL OF BLEEDING IN SEVERELY UREMIC PATIENTS UNDERGOING ORAL-SURGERY [J].
BUCKLEY, DJ ;
BARRETT, AP ;
KOUTTS, J ;
STEWART, JH .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1986, 61 (06) :546-549
[10]   CONSISTENCY OF RESPONSES TO SEPARATE DESMOPRESSIN INFUSIONS IN PATIENTS WITH STORAGE POOL DISEASE AND ISOLATED PROLONGED BLEEDING-TIME [J].
CASTAMAN, G ;
RODEGHIERO, F .
THROMBOSIS RESEARCH, 1993, 69 (04) :407-412